JP2019503172A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503172A5
JP2019503172A5 JP2018533745A JP2018533745A JP2019503172A5 JP 2019503172 A5 JP2019503172 A5 JP 2019503172A5 JP 2018533745 A JP2018533745 A JP 2018533745A JP 2018533745 A JP2018533745 A JP 2018533745A JP 2019503172 A5 JP2019503172 A5 JP 2019503172A5
Authority
JP
Japan
Prior art keywords
domain
amino acid
antibody
residue
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018533745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/068808 external-priority patent/WO2017117179A1/en
Publication of JP2019503172A publication Critical patent/JP2019503172A/ja
Publication of JP2019503172A5 publication Critical patent/JP2019503172A5/ja
Priority to JP2021087487A priority Critical patent/JP2021119793A/ja
Pending legal-status Critical Current

Links

JP2018533745A 2015-12-28 2016-12-28 定常領域の変異を有する二重特異性抗体およびその使用 Pending JP2019503172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021087487A JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271844P 2015-12-28 2015-12-28
US62/271,844 2015-12-28
PCT/US2016/068808 WO2017117179A1 (en) 2015-12-28 2016-12-28 Bispecific antibodies having constant region mutations and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021087487A Division JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2019503172A JP2019503172A (ja) 2019-02-07
JP2019503172A5 true JP2019503172A5 (enExample) 2020-02-13

Family

ID=57822093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018533745A Pending JP2019503172A (ja) 2015-12-28 2016-12-28 定常領域の変異を有する二重特異性抗体およびその使用
JP2021087487A Pending JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021087487A Pending JP2021119793A (ja) 2015-12-28 2021-05-25 定常領域の変異を有する二重特異性抗体およびその使用

Country Status (7)

Country Link
US (1) US11459405B2 (enExample)
EP (1) EP3397646A1 (enExample)
JP (2) JP2019503172A (enExample)
CN (1) CN108779182A (enExample)
AU (1) AU2016381605A1 (enExample)
CA (1) CA3010027A1 (enExample)
WO (1) WO2017117179A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102411491B1 (ko) 2012-11-28 2022-06-22 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
RS66622B1 (sr) 2015-10-08 2025-04-30 Zymeworks Bc Inc Antigen-vezujući polipeptidni konstrukti koji sadrže kapa i lambda lake lance, i njihove upotrebe
EP3504234A4 (en) 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
KR102247704B1 (ko) 2016-11-18 2021-05-03 북경한미약품 유한공사 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
KR102471868B1 (ko) * 2018-01-15 2022-11-30 아이-맵 바이오파마 유에스 리미티드 변형된 Cκ 및 CH1 도메인
WO2019153200A1 (zh) * 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
KR20200120927A (ko) * 2018-02-11 2020-10-22 베이징 한미 파마슈티컬 컴퍼니 리미티드 항-pd-1/항-vegf 천연 항체 구조-유사 이형이량체형 이중특이성 항체 및 그의 제조
BR112020022179A2 (pt) 2018-05-03 2021-02-02 Genmab B.V. primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit.
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020109627A1 (en) * 2018-11-30 2020-06-04 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
AU2020315282A1 (en) * 2019-07-12 2022-02-10 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
WO2021163031A1 (en) * 2020-02-12 2021-08-19 Eli Lilly And Company Crystallization of antibodies or antigen-binding fragments
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP5522405B2 (ja) * 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
EA201791693A1 (ru) * 2011-03-25 2018-05-31 Гленмарк Фармасьютикалс С.А. Гетеродимерные иммуноглобулины
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
WO2013065708A1 (ja) 2011-10-31 2013-05-10 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR102411491B1 (ko) 2012-11-28 2022-06-22 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
CN105764922B (zh) * 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2015173756A2 (en) * 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
BR112016027888A2 (pt) * 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
AU2018281045A1 (en) * 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations

Similar Documents

Publication Publication Date Title
US20240158513A1 (en) FC Variants and Methods for Their Production
JP6161540B2 (ja) Fc変異体及びそれらの生産方法
RU2573915C2 (ru) Содержащие суперспираль и/или привязку белковые комплексы и их применение
US11459405B2 (en) Bispecific antibodies having constant region mutations and uses therefor
JP6048972B2 (ja) ヘテロ多量体タンパク質の産生
JP2019503172A5 (enExample)
JP7253518B2 (ja) 哺乳動物細胞を用いたヘテロ多量体タンパク質の生成